-

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, will participate in the following conference:

33rd Annual Piper Sandler Healthcare Conference
November 29 – December 2, with a fireside chat webcast available beginning Monday, November 22, 2021 at 10:00 a.m. ET / 7:00 a.m. PT

About Tenaya Therapeutics

Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.

Contacts

Investors:
Leone Patterson
Tenaya Therapeutics
IR@tenayathera.com

Media:
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Release Summary
Tenaya Therapeutics announced today that Faraz Ali, Chief Executive Officer, will participate in the 33rd Annual Piper Sandler Healthcare Conference.
Release Versions

Contacts

Investors:
Leone Patterson
Tenaya Therapeutics
IR@tenayathera.com

Media:
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com

Social Media Profiles
More News From Tenaya Therapeutics, Inc.

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today announced that it has completed the build-out and operational launch of its Genetic Medicines Manufacturing Center....

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced that it will present preclinical data at the European Society of Cardiology (ESC) Heart Failure 2022 conference....

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics today provided business and program updates, and reported financial results for the first quarter ended March 31, 2022....
Back to Newsroom